Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Peter Walter was chosen ... for his pioneering work on how proteins are transported ... a regulatory mechanism that cells use to handle stress ... is a professor of biochemistry at the University of ... treating a range of human diseases related to defective ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... 12 months ended December 31, 2014.  ... or ($0.05) per share, for the three months ended ...
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based ... and executive appointments effective immediately. , Mike Catelani will ... member of the Board of Directors. Daniel Head is ... Dowden will assume the position of Senior Director of ... Officer (COO), has been appointed to the position of ...
(Date:3/26/2015)... , March 26, 2015  BioNano Genomics, Inc., the ... Terry Salyer as chief commercial officer. Salyer has ... worldwide sales teams in life sciences. At BioNano, Salyer ... System, a genome-mapping platform to assemble a comprehensive view ... variations. To date, 32 institutions located in ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3
... & Forbes Holdings Inc.,announced today the appointment of ... Administrative Officer. As Chief Administrative Officer,Mr. Schwartz will ... the Company,s businesses. Mr. Schwartz will also,continue, for ... Forbes,s,General Counsel. "Barry has been an exemplary ...
... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the ... to construct an $11 million, state-of-the-art BioCenter,for the ... at the site of its existing bioprocess production ... is a response to the increasing demand for,disposable ...
... Oct. 11 More than half of,Massachusetts CEOs are ... the current state and national economies, according to,a new ... Massachusetts,Economic Assessment and Analysis Project (MEAAP) -- a joint ... of those surveyed said their own businesses were,growing compared ...
Cached Biology Technology:MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman 2Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers 2Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers 3Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers 4Survey Sees Mass. CEOs as Bullish on Own Businesses 2
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the ... Business Report" report to their offering. This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ...
(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... available in French and German . ... public attention. In particular silver nanoparticles are being investigated in ... authorities. The assumption behind this interest is that they are ... Nowack and Harald Krug, together with Murray Heights of the ...
... the inner lining of our blood vessels and ... platelet adhesion and immune function. Endothelial dysfunction is ... of arteries and arterioles to dilate fully. ... is a key factor in the development of ...
... rising greenhouse gas emissions effectively has led to intensifying ... the rate at which Earth is heating up. The ... have now released the first summary for policymakers on ... authors report that the chances of success of using ...
Cached Biology News:Nanosilver: A new name -- well-known effects 2Nanosilver: A new name -- well-known effects 3Young rats given polyphenols show less endothelial function deterioration with aging 2Ocean fertilization summary for policymakers published 2
...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
... This book is unique in that ... techniques currently used in the diagnosis ... virus-specific antibodies and clinical virus isolates. ... blotting and hybridization procedures, PCR for ...
...
Biology Products: